HIF1A and neoplasm: To determine the DNA methylation status of EGLN1-3 and HIF1A promoter regions in both tumor and normal tissues in our patient cohort (n = 77), we used methylation-sensitive High-Resolution Melting Analysis (MS-HRM) (Figure 5A,B).